NCT04554056View on ClinicalTrials.gov

Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

586

Participants

Timeline

Start Date

September 21, 2020

Primary Completion Date

August 20, 2022

Study Completion Date

November 5, 2022

Conditions
Breast Cancer Female
Interventions
DRUG

MW05

Recombinant (yeast secreted) human serum albumin-human granulocyte colony stimulating factor (I) fusion protein injection

DRUG

PEG-rhG-CSF

PEGylated Recombinant Human Granulocyte Colony-Stimulating Factor

Trial Locations (1)

Unknown

Fudan University Affiliated Cancer Hospital, Shanghai

All Listed Sponsors
lead

Mabwell (Shanghai) Bioscience Co., Ltd.

INDUSTRY

NCT04554056 - Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF | Biotech Hunter | Biotech Hunter